For newborns and infants, whose immune systems are still developing, and airways are small, RSV can quickly become serious.

COVID-19 activity is rising in much of the country. Data shows overall respiratory virus spread is very low in the U.S.

For a small group of people scattered across the world, living with a rare immune condition comes with an unexpected twist: ...

Palivizumab injection (Synagis), an RSV prevention therapy for children, is being discontinued and will no longer be available as of December 31, 2025.